The slowing market for dental implants continues to affect Nobel Biocare's financials.
The company reported a net profit of 27.7 million euros ($34.5 million) on revenues of 296.5 million euros ($370 million) for the first half of 2012 (end-June 30), compared with a net profit of 28.8 million euros ($35.9 million) on revenues of 286.4 million euros ($357 million) for the first half of 2011.
"In a slowing implant market, the NobelActive implant family continues to grow at double-digit rates in terms of volume and value, while the revenue from the other implant brands and standardized abutments remains soft," the company noted in a press release.
In the first half of 2012, markets developed less favorably than anticipated at the beginning of the year, according to Nobel Biocare. For the remainder of 2012, the company anticipates a continuation of the challenging economic circumstances in many countries and expects the market to develop at the same pace as in the first half.
